Technology Information

Asthma Treatment by Inhibition of CaMKII

Calcium/Calmodulin Dependent Protein Kinase II (CamKII) has been shown to play a role in contraction of smooth muscle in various locations throughout the body.
UIRF Case #:09008


Relevant PublicationsLevel of Development
Technology DescriptionInventor Web Site Link
Patent LinksContact Information
Other Information 

Relevant Publications

Level of Development

General: Experimental Proof of Concept

Technology Description

Researchers at the University of Iowa have identified novel compounds that may be used to reverse the smooth muscle constriction and inflammation of asthma by inhibiting CaMKII signaling. CaMKII has several roles in the body including pro-constriction signaling in smooth muscle cells in the airway and other tissue types. The small molecule KN-93 as well as aryl-indoyl maleimide and several derivatives of each have been shown to inhibit CamKII-delta, which appears to be the primary isoform responsible for this activity. Inhalation of these compounds, which is the typical administration route for asthma therapeutics, could be an effective therapeutic option for patients suffering from asthma symptoms.

Inventor Web Site Link(s)

http://www.medicine.uiowa.edu/dept_primary_apr.aspx?appointment=Internal%20Medicine&id=andersonmar

Patent Link(s)

US8440656    

Contact Information

Sean Kim
hyeon-kim@uiowa.edu
319-335-4607

6 Gilmore Hall, 112 N. Capitol Street, Iowa City, IA 52242     phone: 319-335-4546 fax: 319-335-4486 © University of Iowa 2007. All rights reserved.